Virtual Library
Start Your Search
T.F. Chen-Yoshikawa
Author of
-
+
P2.02 - Poster Session with Presenters Present (ID 462)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Locally Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.02-022 - For down Staged Clinical N3 M0 Non-Small Cell Lung Cancer Patients Chemo-Radiotherapy Followed by Surgery Can Improve Survival (ID 5830)
14:30 - 14:30 | Author(s): T.F. Chen-Yoshikawa
- Abstract
Background:
Non-small cell lung cancer (NSCLC) patients with clinical (c-) N3 M0 are conventionally regarded as inoperable. However, the role of surgery for such patients clinically down staged after chemo-radiotherapy has not been ascertained. We retrospectively compared the outcome after chemo-radiotherapy plus surgery for down staged patients versus only conventional chemo-radiotherapy.
Methods:
Patients treated at our institute from 2000 to 2016 for primary NSCLC with c-N3M0 were identified. Amongst them, six patients received lung resection surgery after chemo-radiotherapy was given and clinical evidence of downstaging found. Fifty patients received only conventional chemo-radiotherapy during the same period. Survival was estimated using the Kaplan-Meier method.
Results:
All of the 6 patients receiving chemo-radiotherapy plus surgery, are recurrence-free survival. The survival time ranged from 5 to 91 months. The 5-year overall survival for the patients receiving surgery was 100% compared with 24% for the 50 patients who did not receive surgery (p= 0.04).
Conclusion:
Our results suggest that the combination of chemo-radiotherapy plus surgery may improve survival for preoperatively down staged c-N3M0 NSCLC patients. These results should be validated by large-scale, prospective, randomized trials.
-
+
P2.04 - Poster Session with Presenters Present (ID 466)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.04-018 - Comprehensive Copy Number Alteration and Gene Expression Analysis of Surgically Resected Thymic Carcinoma (ID 4725)
14:30 - 14:30 | Author(s): T.F. Chen-Yoshikawa
- Abstract
Background:
Thymic carcinoma is rare and comparatively poor prognostic. Due to its rarity, our knowledge of treatments and prognostic biomarkers available for these tumors is limited. Previous reports revealed low genetic mutation frequency of the tumors, and the inverse correlation between the frequency of genetic mutation and copy number alteration (CNA). Based on these reports, we hypothesized tumorigenesis of thymic carcinomas is mostly caused by copy number and transcriptional alterations. To substantiate the hypothesis, we extracted and analyzed CNA and gene expression data from surgical samples to elucidate driver genes, druggable targets and prognostic factors.
Methods:
Between January 2009 and March 2016, patients underwent surgery for thymic epithelial tumor in our institution were reviewed. RNA and DNA of the tumors were extracted from FFPE operative samples, gene expression data were obtained by GeneChip Human Transcriptome Array 2.0 (affymetrix), and CNA were detected by OncoScan (affymetrix). These results were analyzed using Transcriptome analysis console (affymetrix) and Nexus expression for OncoScan (BioDiscovery). Upregulated genes in copy number gained region and down regulated genes in copy number lost region were selected as a candidate of tumorigenesis of thymic carcinoma.
Results:
We had 10 thymic squamous cell carcinoma samples. As a comparison, we use three samples of type A thymoma. CNA data from thymic squamous cell carcinoma showed similar characteristics, chromosome 1q gain, 6p and q loss, and 16q loss, corresponding with previous reports. Gene expression analysis of thymic carcinoma in comparison with type A thymoma revealed down regulation of the genes, BRD2, HSP90AB1, FOXO3, and MARCKS in chromosome 6, and MTSS1L in chromosome 16q. Figure 1
Conclusion:
We reported the results of genome wide gene expression and CNA analysis. We extracted some candidate genes, but farther validations are needed.
-
+
P3.01 - Poster Session with Presenters Present (ID 469)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.01-048 - Cigarette Smoking is Associated with Epithelio-Mesenchymal Transition in Human Adenocarcinoma (ID 5531)
14:30 - 14:30 | Author(s): T.F. Chen-Yoshikawa
- Abstract
Background:
Cigarette smoking (CS) is well known to cause lung cancer. In addition to the mechanisms of tumorigenesis of lung cancer with CS, a lot of evidences are currently accumulating that CS induces epithelio-mesenchymal transition (EMT) in tumor cells. The correlation of CS with the malignant properties of lung cancer remained elusive in clinical settings. Here we examined the clinical significance of CS with regard to EMT and malignant progression in human lung adenocarcinoma.
Methods:
Clinical samples were obtained from the 239 cases of resected lung adenocarcinoma which were consecutively operated from January 2001 to December 2007 in our institution. Pathological stage distribution of the cases by TNM classification (WHO, 7th edition) was below: 1A: 118, 1B: 71, 2A: 22, 2B: 4, 3A: 23, 3B: 1. Smoking history was taken from all the patients, then their smoking status were classified into 3 groups according to the Brinkman Index (Non;0, n=109: Light;1~400, n=29: Heavy;401~, n=101). The samples were immunostained against E-cadherin and Vimentin using tissue microarrays of resected specimens to assess the activation level of EMT. Then, we classified into 3 groups: the group ‘N’, E-cadherin(E+) and Vimentin(V-), “null” EMT activation; the group ‘F’, E-/V+, ‘full’ EMT; the group ‘P’, E-/V- or E+/V+, ‘partial’ EMT. The numbers of the group F/ P/ N were 38/ 93/ 108, respectively. Furthermore, DNA samples were extracted from frozen surgical samples and the mutations for the hot-spot exons of EGFR, K-ras, and p53 were detected by SSCP or direct sequencing methods. The differences of survival duration, pathological invasive factors, DNA mutations and EMT activation level were statistically analysed among smoking groups.
Results:
Significant difference was found in 5-year survival rate among 3 smoking groups: Non, 89.1%; Light, 89.5%; Heavy, 61.7%. Smoking status was significantly associated with EMT activation, DNA mutation status, local invasive factors, and lymph-node metastasis. In the tumors harboring either wild-type K-ras or wild-type p53, heavy smoking was associated with EMT activation (p<0.0001, p=0.0002, respectively), whereas no correlation with regard to EGFR staus.
Conclusion:
Smoking amounts had a significant association with EMT activation level and malignant progression of human adenocarcinoma. Heavy smoking was related with EMT activation of the tumors either with wild-type K-ras or p53.
